Wize Pharma s Takeover Offer for Cosmos Capital Declared Unconditional
USA - English
News provided by
Share this article
Share this article
HOD HASHARON, Israel, Feb. 16, 2021 /PRNewswire/ Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that it has declared its previously announced off-market takeover offer ( Offer ) for all of the ordinary shares in Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia ( Cosmos ), free from all of the conditions set out in the Offer and, accordingly, the Offer has become unconditional. A formal notice of the unconditionality of the Offer, as required under section 650F of the Corporations Act 2001 (Australia), is attached as Annexure A below.
, 2021 /PRNewswire/ -
InMed Pharmaceuticals Inc. ( InMed or the Company ) (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ( CBN ), today announced that it has closed the previously announced private placement.
Under the terms of the private placement, an aggregate of 1,050,000 units were purchased, each unit comprised of one common share and 0.66 of a warrant to purchase one common share, at a placement price of US$4.25 per unit. The warrants have an exercise price of US$4.85, are exercisable six months following issuance, and have a term of five and one half years following issuance. After the placement agent fees and estimated offering expenses payable by the Company, the Company expects to receive net proceeds of approximately US$4.0 million.
Share this article
Share this article
SEATTLE, Feb. 16, 2021 /PRNewswire/ Quark Expeditions, the recognized leader in Polar Adventures, has secured rapid onsite testing capability as part of its industry-leading S.A.F.E. COVID Policy, designed to protect travelers health and financial investment when expedition travel resumes.
(PRNewsfoto/Quark Expeditions) The ship-based travel industry has had a difficult time bouncing back from this global pandemic, said Andrew White, President of Quark Expeditions. To protect guests and crew from COVID-19 when normal operations resume, we ve adopted rapid onsite PCR testing capability that s recognized around the world as the gold standard of COVID testing. We re committed to reducing the risk of a COVID outbreak and get people back to exploring the remote, naturally social-distanced Polar Regions.
Share this article
Share this article
SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ The global preparative and process chromatography market size is expected
to reach USD 17.26 billion by 2028, according to a new report by Grand View Research, Inc. It is expected
to expand at a CAGR of 11.65% from 2021 to 2028. High demand for monoclonal antibodies, coupled with the growing adoption of preparative chromatographic techniques in the bioprocessing industry, is anticipated to boost the revenue growth in the market over the forecast period.
Key suggestions from the report:
By product, process chromatography accounted for the largest revenue share in 2020 owing to the growing research activities and adoption of automated systems in the field of biopharmaceuticals